tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Maxwell Skor, 15 are a BUY (75%), 5 are a HOLD (25%).
Analyst Maxwell Skor, currently employed at MORGAN STANLEY, carries an average stock price target met ratio of 52.08% that have a potential upside of 34.47% achieved within 88 days.
Maxwell Skor’s has documented 41 price targets and ratings displayed on 8 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on RARE, Ultragenyx at 18-Sep-2026.
Analyst best performing recommendations are on CDTX (CIDARA THERAPEUTICS).
The best stock recommendation documented was for CDTX (CIDARA THERAPEUTICS) at 10/19/2025. The price target of $190 was fulfilled within 26 days with a profit of $88.48 (87.16%) receiving and performance score of 33.52.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 16-Oct-2025
$287
$59.13 (25.95%)
$271
22 days ago
(15-Sep-2026)
2/3 (66.67%)
$47.23 (19.70%)
246
Buy Since 20-Mar-2020
$312
$84.13 (36.92%)
$262
1 months 5 days ago
(02-Sep-2026)
14/15 (93.33%)
$44.69 (16.72%)
921
Buy Since 02-Jul-2025
$273
$45.13 (19.81%)
$275
1 months 6 days ago
(01-Sep-2026)
2/4 (50%)
$12.75 (4.90%)
321
Buy Since 02-May-2025
$327
$99.13 (43.50%)
$273
1 months 6 days ago
(01-Sep-2026)
4/5 (80%)
$66.75 (25.65%)
102
Buy Since 27-Aug-2026
$344
$116.13 (50.96%)
$345
1 months 6 days ago
(31-Aug-2026)
0/2 (0%)
$80.96 (30.78%)
Which stock is Maxwell Skor most bullish on?
Which stock is Maxwell Skor most reserved on?
What Year was the first public recommendation made by Maxwell Skor?
